GLP-1 receptor agonists and obesity-related cancer risk
GLP-1 agonists, the new weight-loss injections, lower weight by 15-20%. Early observational data suggest fewer obesity-related cancers in people who take them, but no trial has yet tested cancer as an outcome.
Obesity is causally linked to at least 13 cancers (IARC 2016). Semaglutide and tirzepatide produce 15-22% weight loss in trials and reduce cardiovascular events (SELECT, NEJM 2023). Several large cohort and target-trial-emulation studies in people with type 2 diabetes report 10-40% lower incidence of obesity-associated cancers (notably endometrial, kidney, liver, pancreatic and colorectal) with GLP-1 receptor agonists compared with insulin or other glucose-lowering drugs, and a signal for lower cancer risk than bariatric surgery in one study; these are observational with short follow-up and prone to immortal-time and surveillance biases. Thyroid C-cell tumours in rodents led to a label warning, with no convincing human medullary thyroid cancer signal so far; pancreatitis and pancreatic cancer concerns have not been borne out. Because these drugs are now used by millions, a randomised trial with cancer incidence as a primary endpoint, or pre-specified cancer endpoints in ongoing outcome trials, is feasible and important.
How it works
Sustained weight loss lowers adiposity-driven insulin, oestrogen and inflammatory signalling; GLP-1 receptor agonists may also have direct anti-proliferative or immunomodulatory effects independent of weight.
- First scalable pharmacological route to reversing the obesity-cancer risk
- Consistent direction of observational signals
- Cardiometabolic benefits already proven
- No randomised cancer endpoint
- Observational biases
- Cost, access and lean-mass loss with rapid weight reduction
Latest papers
topQuery for this technology: (TITLE:"GLP-1 receptor agonists and obesity-related cancer risk" OR ABSTRACT:"GLP-1 receptor agonists and obesity-related cancer risk") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GLP-1 receptor agonists and obesity-related cancer risk, not a curated reading list.
Pages like this
not linked directly; found by shared links- Key paperIARC verdict: excess body fat causes 13 cancers
Shares A trial of GLP-1 weight-loss drugs with cancer as the primary outcome, Funding follows fashion, not burden, Endometrial cancer, Prevention we already have is not deployed.
- TechnologyStructured exercise programmes after curative treatment
Shares Metabolic syndrome and insulin resistance, Energy balance, Dietitian-led weight-loss programmes in HR-positive breast cancer, Obesity-related cancers (IARC list of 13).
- TrialBWEL (Breast Cancer Weight Loss, Alliance A011401)
Shares GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer, Energy balance, Dietitian-led weight-loss programmes in HR-positive breast cancer, Obesity-related cancers (IARC list of 13).
- TechnologyTime-restricted eating in cancer prevention and survivorship
Shares Metabolic syndrome and insulin resistance, Energy balance, Prevention we already have is not deployed, HR-positive / HER2-negative breast cancer.
- TechnologyUltra-processed food and sugar-sweetened drinks
Shares Obesity-related cancers (IARC list of 13), Prevention we already have is not deployed, Hepatocellular carcinoma, Pancreatic ductal adenocarcinoma.
- TechnologyMediterranean and plant-forward dietary patterns
Shares Energy balance, Lipid synthesis, uptake & cholesterol, Prevention we already have is not deployed, Hepatocellular carcinoma.
- TermGlycaemic index and glycaemic load
Shares Metabolic syndrome and insulin resistance, Energy balance, Endometrial cancer, Colorectal cancer.
- TechnologyAlcohol reduction, pricing and cancer warning labels
Shares Chemoprevention & risk-reducing surgery, Prevention we already have is not deployed, Hepatocellular carcinoma, HR-positive / HER2-negative breast cancer.